Print Friendly, PDF & Email

Piotr Lassota, PhD

R&D Director

M.S. with honors from the Dept. of Chemistry, University of Warsaw. Ph.D. in biochemistry from the Institute of Biochemistry and Biophysics, Polish Academy of Sciences. Post-doctoral training at Sloan Kettering Institute in New York, NY. First faculty position at the Sloan Kettering Institute, then at the New York Medical College. Joined US Pharma industry in 1992 (American Cyanamid, then Wyeth). Between 1997 and 2006 at Novartis, in roles of increasing responsibility, including an Executive Director of the Pharmacology Unit in the Oncology Therapeutic Area, and a member of the Oncology Therapeutic Area Board. Led pharmacology team developing now marketed drug, Farydak. From 2006 till 2009 a Divisional Vice President at Caliper Life Sciences responsible for the biology of non-invasive visible light imaging. Developed methods allowing visualization of individual, luciferase-labeled cells in live animals. In 2010 joined Polpharma as a member of the management board, CSO and Director of the newly formed Polpharma Biologics Division. Established Polpharma Biologics from scratch at the Gdansk Biotechnology Park, with first labs opened in Dec of 2012. In 2014 established a software company dedicated to development of software for pharmacometric calculations, where serves as a CEO. From mid-2016 to mid-2018 a CEO of a Polish biotech company BLIRT in Gdansk. Refocused BLIRT on professional protein manufacturing and created industrial scale production facility for it. Author/co-author of more than 30 scientific publications, 9 patents and more than 50 publication quality industrial reports. Experienced in development of oncology therapeutics (small molecules and biologics), pharmacology (in vitro and in vivo), and non-invasive visible light imaging.

Print Friendly, PDF & Email
Posted by Bartosz Solarewicz, Posted on 11.03.2019